Effect of novel non-peptidic delta opioid receptor antagonists on human T and B cell activation

Life Sciences

Volumn 75, Issue 1, 2004, Pages 63-75

  D'Ambrosio, Antonella ^a   Noviello, Lia ^b   Negri, Lucia ^b   Schmidhammer, Helmut ^c   Quintieri, Francesca ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

opioid antagonists; Immunosuppression; Opioid receptors

Indexed keywords

ALLOANTIGEN; ANTIGEN; DELTA OPIATE RECEPTOR ANTAGONIST; INTERLEUKIN 2; MITOGENIC AGENT; MONOCLONAL ANTIBODY CD3; NALTRINDOLE; SUPERANTIGEN;

ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL STRAIN; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN SECRETION; STAPHYLOCOCCUS AUREUS; STIMULUS; T LYMPHOCYTE ACTIVATION;

B-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MITOGENS; NALTREXONE; RECEPTORS, OPIOID, DELTA; T-LYMPHOCYTES;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 16544368269     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.12.003     Document Type: Article

References (35)

1. Arakawa K., Akami T., Okamoto M., Akioka K., Nakai I., Oka T., Nagase H. Immunosuppression by delta opioid receptor antagonist. Transplantion Proceedings. 25(1):1993;738-740.
2. Arakawa K., Akami T., Okamoto M., Nakajima H., Mitsuo M., Nakai I., Oka T., Nagase H., Matsumoto S. Immunosuppressive effect of delta-opioid receptor antagonist on xenogenic mixed lymphocyte reaction. Transplantation Proceedings. 24:1992;696-697.
3. Bayer B.M., Daussin S., Hernandez M., Irvin L. Morphine inhibition of lymphocyte activity is mediated by an opioid-dependent mechanism. Neuropharmacology. 29(4):1990;369-374.
4. Bayer B.M., Gastonguay M.R., Hernandez M.C. Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist sensitivity and naltrexone reversibility. Immunopharmacology. 23(2):1992;117-124.
5. Biyashev D., Monory K., Benyhe S., Schütz J., Koch M., Schmidhammer H., Borsodi A. Novel delta-opioid -receptor-selective ligands in the 14-alkoxy-substituted indolo- and benzofuromorphinan series. Helvetica Chimica Acta. 84:2001;2015-2021.
6. Calder P.C., Kew S. The immune system: a target for functional foods? British Journal of Nutrition. 88:2002;S165-S176.
7. Caroleo M.C., Arbitrio M., Melchiorri D., Nistico' G. A reappraisal of the role of the various opioid receptor subtypes in cell mediated immunity. Neuroimmunomodulation. 1(2):1994;141-147.
8. Carr D.J.J., DeCosta B.R., Jacobson A.E., Rice K.C., Blalock J.E. Corticotropin releasing hormone augments natural killer cell activity through a naloxone-sensitive pathway. Journal of Neuroimmunology. 28:1990;53-61.
9. Carr D.J.J., Kim C.-H., DeCosta B., Jacobson A.E., Rice K.C., Blalock J.E. Evidence for δ-class opioid receptor on cells of the immune system. Cellular Immunology. 116:1988;44-51.
10. Chuang L.F., Chuang T.K., Killam K.F. Jr., Chuang A.J., Kung H., Yu L., Chuang R.Y. Delta opioid receptor gene expression in lymphocytes. Biochemical and Biophysical Research Communications. 202:1994;1291-1299.
11. Chuang T.K., Killam K.F. Jr., Chuang L.F., Kung H.F., Sheng W.S., Chao C.C., Yu L., Chuang R.Y. Mu opioid receptor gene expression in immune cells. Biochemical and Biophysical Research Communications. 216:1995;922-930.
12. Eisenstein T.K., Hilburger M.E. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. Journal of Neuroimmunology. 83:1998;36-44.
13. Gaveriaux C., Peluso J., Simonin F., Laforet J., Kieffer B. Identification of κ- and δ-opioid receptor transcripts in immune cells. FEBS Letters. 369:1995;272-276.
14. Gavériaux-Ruff C., Filliol D., Simonin F., Matthes H.W.D., Kieffer B.L. Immunosuppression by δ-opioid antagonist naltrindole: δ and triple υ/δ/κ-opioid receptor knockout mice reveal a nonopioid activity. Journal of Pharmacology and Experimental Therapeutics. 298:2001;1193-1198.
15. House R.V., Thomas P.T., Kozak J.T., Bhargava H.N. Suppression of immune function by non peptidic delta opioid receptor antagonists. Neuroscience letters. 198:1995;119-122.
16. House R.V., Thomas P.T., Bhargava H.N. A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides. Peptides. 17:1996;75-81.
17. Makarenkova V.P., Esche C., Kost N.V., Shurin G.V., Rabin B.S., Zozulya A.A., Shurin M.R. Identification of delta- and mu-type opiod receptors on human and murine dendritic cells. Journal of Neuroimmunol. 117:2001;68-77.
18. Mazumder S., Nath I., Dhar M.M. Immunomodulation of human T cell responses with receptor selective enkephalins. Immunology Letters. 35:1993;33-38.
19. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., Rogers T.J. Opioids, opioid receptors, and the immune response. Drug and Alcohol Dependence. 62:2001;111-123.
20. Norman D.J. Mechanisms of action and overwiew of OKT3. Ther Drug Monit. 17(6):1995;615-620.
21. Noviello L., Papadia S., Capobianchi M.R., Negri L. Immunomodulatory responses to delta opioid receptor ligands in human lymphocytes. European Journal of Pharmacology. 332:1997;R1-R2.
22. Sander B., Brigati C., Moller E. Inhibition of in vitro alloreactivity by cyclosporin A: evidence for an inter-individual variation in sensitivity. Scandinavian Journal of Immunology. 23:1986;435-440.
23. Schütz J., Dersch C.M., Horel R., Spetea M., Koch M., Meditz R., Greiner E., Rothman R.B., Schmidhammer H. Synthesis and biological evaluation of 14-alkoxymorphinans. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans. Journal of Medicinal Chemistry. 45(24):2002;5378-5383.
24. Sharon N. Lectin receptors as lymphocyte suface markers. Advances in Immunology. 34:1983;213-298.
25. Sharp B.M., Eisenstein T. Expression of opioid receptor by immune cells. Journal of Neuroimmunology. 69:1996;3-13.
26. Sharp B.M., Roy S., Bidlack J.M. Evidence for opioid receptors on cells involved in host defence and the immune system. Jounal of Neuroimmunology. 83:1998;45-56.
27. Sibinga N.E.S., Goldstein A. Opioid peptides and opioid receptors in cells of the immune system. Annual Review in Immunology. 6:1988;219-249.
28. Silverman G.J. B-cell superantigens. Immunology Today. 18(8):1997;379-386.
29. Silverman G.J. B-cell superantigens: possible roles in immunodeficiency and autoimmunity. Seminars in Immunology. 10:1998;43-55.
30. Spetea M., Harris H.E., Berzetei-Gurske I.P., Klareskog L., Schidhammer H. Binding, pharmacological and immunological profiles of the δ-selective opioid receptor antagonist HS 378. Life Sciences. 69:2001;1775-1782.
31. 1 progression and c-myb expression. Science. 233(4760):1986;203-206.
32. Van Wauwe J.P., De Mey J.R., Goossens J.G. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. Journal of Immunology. 124(6):1980;2708-2713.
33. Wick M.J., Minnerath S.R., Roy S., Ramakrishnan S., Loh H.H. Differential expression of opioid receptor genes in human lymphoid cell lines and peripheral blood lymphocytes. Journal of Neuroimmunology. 64:1996;29-36.
34. Yeh C.J., Hsi B.L., Faulk W.P. Propidium iodide as a nuclear marker in immunofluorescence: II. Use with cellular identification and viability studies. J Immunological Methods. 43(3):1981;269-275.
35. Zouali M. B-cell superantigens: implications for selection of the human antibody repertoire. Immunology Today. 16(8):1995;399-405.